AOD-9604 vs Semaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Also: Ozempic, Wegovy
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.
Key Comparison Insights
- Semaglutide is FDA approved, while AOD-9604 remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide has stronger research evidence (FDA Approved) compared to AOD-9604 (Human Trials).
Detailed Comparison
| Attribute | AOD-9604 | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | AOD-9604 mimics the lipolytic (fat-burning) effects of growth hormone without affecting blood sugar or tissue growth. It stimulates lipolysis and inhibits lipogenesis by interacting with beta-3 adrenergic receptors on fat cells. | Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1. |
| Common Dosing | 300 mcg daily Once daily, usually morning fasted | 1-2.4 mg weekly (after titration) Once weekly |
| Administration | Subcutaneous injection or oral (studied both) | Subcutaneous injection weekly, or oral (Rybelsus) |
| Typical Duration | 12-24 weeks in studies | Long-term / chronic use |
| Best Time to Take | Morning (fasted) | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Clinical trials showed modest weight loss effects but failed to meet primary endpoints for FDA approval. Some studies show cartilage regeneration potential. Research demonstrates safety profile similar to placebo with no significant GH-like side effects. | STEP trials demonstrated average weight loss of 15-17% body weight over 68 weeks. SELECT trial showed 20% reduction in major cardiovascular events. Proven efficacy for glycemic control in type 2 diabetes with A1C reductions of 1.5-2%. |
Frequently Asked Questions: AOD-9604 vs Semaglutide
What is the difference between AOD-9604 and Semaglutide?
AOD-9604 is a weight loss peptide that a modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full gh. Semaglutide is a weight loss peptide that a glp-1 receptor agonist fda-approved for type 2 diabetes and chronic weight management. one of the most effective pharmaceutical weight loss interventions available. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AOD-9604 or Semaglutide?
Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while Semaglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AOD-9604 and Semaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and Semaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of AOD-9604 and Semaglutide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.